Alps Advisors Inc Cytokinetics Inc Transaction History

Alps Advisors Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	SELL	$33.36 - $45.71 $47,804 - $65,502	-1,433 Reduced 2.23%	62,694 $2.21 Million
Q4 2022 Feb 14, 2023	BUY	$35.77 - $51.11 $455,244 - $650,476	12,727 Added 24.76%	64,127 $2.94 Million
Q3 2022 Nov 14, 2022	BUY	$38.54 - $54.52 $22,661 - $32,057	588 Added 1.16%	51,400 $2.49 Million
Q2 2022 Aug 11, 2022	SELL	$33.93 - $48.92 $1.2 Million - $1.73 Million	-35,396 Reduced 41.06%	50,812 $2 Million
Q1 2022 May 16, 2022	SELL	$29.74 - $46.0 $323,065 - $499,698	-10,863 Reduced 11.19%	86,208 $3.17 Million
Q4 2021 Feb 09, 2022	SELL	$34.35 - $46.38 $181,471 - $245,025	-5,283 Reduced 5.16%	97,071 $4.42 Million
Q3 2021 Nov 15, 2021	BUY	$18.54 - $35.74 $145,761 - $280,987	7,862 Added 8.32%	102,354 $3.66 Million
Q2 2021 Aug 11, 2021	SELL	$19.79 - $26.99 $676,026 - $921,978	-34,160 Reduced 26.55%	94,492 $1.87 Million
Q1 2021 May 07, 2021	BUY	$18.57 - $25.68 $22,543 - $31,175	1,214 Added 0.95%	128,652 $2.99 Million
Q4 2020 Feb 03, 2021	BUY	$15.26 - $28.61 $1.94 Million - $3.65 Million	127,438 New	127,438 $2.65 Million

410

125M

4.6M

2.43M

Ticker CYTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,144,096
Market Cap $4.62B
Description
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.